Pfizer Inc
Long book
$238.8M
Q1 2026
Positions
18
Top-10 weight
96%
concentration
Last quarter
-5.7%
SPY +14.8%
Turnover
11%
of book per quarter
Strategy in plain words
auto-generated from filingsPfizer Inc is a concentrated fundamental stock-picker, specialised in healthcare (100% of the long book), running a $238.8M US long book across 18 positions.
The portfolio is extremely concentrated — the top 10 positions are almost the whole book. Turnover is modest: positions are typically held for years. Current anchor positions: ORIC PHARMACEUTICALS INC, ALLOGENE THERAPEUTICS INC, ARVINAS INC, CELCUITY INC, ZURA BIO LTD.
Over the last 6 quarters its long book ran on average 0.6pp per quarter ahead of the S&P 500, beating the index in 4 of 6 quarters. We rate its filings highest-signal: new buys here are worth attention.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q4 2024
-1.5%
Q1 2025
+15.5%
Q2 2025
+3.7%
Q3 2025
+4.8%
Q4 2025
+14.6%
Q1 2026
-5.7%
Sector allocation
Healthcare 100%
Technology 0%
Long book by quarter
What does Pfizer Inc own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| ORIC ORIC PHARMACEUTICALS INC | Healthcare | 4.8M | $57.7M | 24.1% | -11.1% |
| ALLO ALLOGENE THERAPEUTICS INC | Healthcare | 22.0M | $49.8M | 20.9% | Held |
| ARVN ARVINAS INC | Healthcare | 3.5M | $34.9M | 14.6% | Held |
| CELC CELCUITY INC | Healthcare | 295.7K | $31.3M | 13.1% | -15.4% |
| ZURA ZURA BIO LTD | Healthcare | 2.8M | $16.8M | 7.1% | -4.4% |
| WVE WAVE LIFE SCIENCES LTD | Healthcare | 1.9M | $11.9M | 5.0% | Held |
| PYXS PYXIS ONCOLOGY INC | Healthcare | 7.0M | $9.2M | 3.9% | Held |
| CRBU CARIBOU BIOSCIENCES INC | Healthcare | 4.7M | $8.3M | 3.5% | Held |
| SPRO SPERO THERAPEUTICS INC | Healthcare | 2.4M | $5.5M | 2.3% | Held |
| BHVN BIOHAVEN LTD | Healthcare | 505.6K | $4.2M | 1.8% | Held |
| CRDF CARDIFF ONCOLOGY INC | Healthcare | 2.4M | $3.7M | 1.6% | Held |
| ZNTL ZENTALIS PHARMACEUTICALS INC | Healthcare | 953.8K | $2.0M | 0.8% | Held |
| NXTC NEXTCURE INC | Healthcare | 153.4K | $1.5M | 0.6% | -2.7% |
| QTTB Q32 BIO INC | Healthcare | 101.6K | $737K | 0.3% | -63.4% |
| BOLT BOLT BIOTHERAPEUTICS INC | Healthcare | 31.3K | $137K | 0.1% | Held |
| DNA GINKGO BIOWORKS HOLDINGS INC | Healthcare | 2.9K | $17K | 0.0% | Held |
| SENS SENSEONICS HOLDINGS INC | Technology | 2.2K | $14K | 0.0% | Held |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 12, 2026 | 21 | $238.8M | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 12, 2026 | 21 | $236.5M | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 13, 2025 | 24 | $437.5M | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 11, 2025 | 24 | $576.2M | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 13, 2025 | 24 | $500.8M | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 26 | $2.59B | canonical | SEC ↗ |